Erdafitinib Balversa 4mg: FGFR Pathway Inhibition in Urothelial Cancer

Overview

Erdafitinib is the first oral FGFR tyrosine-kinase inhibitor approved for urothelial carcinoma, and its place is defined by the FGFR pathway. It is used after platinum-based chemotherapy in tumors that carry a susceptible FGFR3 genetic alteration, confirmed by testing. Rather than being given as a fixed partner in one regimen, it occupies the FGFR pathway and is often sequenced around platinum chemotherapy or immunotherapy depending on the case. The 4 mg tablet allows the start dose and the later increase to be built from a single strength, which simplifies dosing for patients managed over many months.

How It Works

Erdafitinib selectively inhibits FGFR1, FGFR2 and FGFR3, blocking the receptor tyrosine-kinase signaling that drives proliferation in FGFR-altered tumors. By occupying the adenosine-triphosphate site of the receptor, it stops the downstream proliferation signal, so cells that depended on constitutive FGFR activation lose their growth advantage. The pathway-focused action is why tumor testing precedes therapy, and why the drug is reserved for the molecular subgroup most likely to respond rather than used broadly across all bladder cancers.

Indications

• Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations
• Disease previously treated with platinum-based chemotherapy
• Used after confirmation of the FGFR genetic change

Dosage & Administration

Start at 8 mg once daily, equal to two 4 mg tablets, and increase to 9 mg if tolerated and phosphate levels allow. Tablets are taken with or without food and swallowed whole. Dose reductions or holds manage high phosphate and other toxicities under clinician supervision during treatment, and the step-up to 9 mg is timed to serum phosphate so efficacy is captured without pushing electrolyte disturbance too far.

Storage & Sourcing

Store at 20 to 25°C in a dry place. Supplied through Janssen GMP lines with lot-specific certificates of analysis. As an ambient-stable oral solid it is straightforward to distribute to oncology pharmacies supporting urothelial cancer care, and the two-tablet start keeps the regimen simple for patients who may already be managing several concurrent medications.

FAQ

Q: When is erdafitinib used?

A: After platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma that carries a susceptible FGFR3 alteration confirmed by testing.

Q: How is the dose adjusted?

A: Start at 8 mg once daily, two 4 mg tablets; if phosphate and tolerance permit, increase to 9 mg, reducing back when toxicity appears.

Q: How does it fit with other therapies?

A: It occupies the FGFR pathway, often sequenced around platinum chemo or immunotherapy rather than given as a fixed combination, per tumor testing.

Q: What monitoring is needed?

A: Phosphate, calcium and eye exams are followed; report vision changes, and manage high phosphate with diet or binders as advised.